Item 5.07 Submission of Matters to a Vote of Security Holders.

As previously disclosed, on April 12, 2022, Sierra Oncology, Inc. (which we refer to as the "Company" or "Sierra Oncology") entered into an Agreement and Plan of Merger (which we refer to as the "Merger Agreement" with GSK plc (formerly GlaxoSmithKline plc) (which we refer to as "GSK") and Orikum Acquisition Inc. (which we refer to as "Acquisition Sub"). We refer to the merger of Acquisition Sub (an indirect wholly owned subsidiary of GSK) with and into Sierra Oncology under the terms of the Merger Agreement as the "Merger."

Sierra Oncology held a special meeting of the stockholders on Wednesday, June 29, 2022, at 10:00 a.m., Pacific time (which we refer to as the "Special Meeting").

The following matters were acted upon at the Special Meeting:



                                                                            BROKER NON-
                                   FOR          AGAINST        ABSTAIN         VOTES

Proposal 1: To adopt the        17,940,827       2,976          62,725           0
Merger Agreement.

Proposal 1 received the
necessary votes to be
approved.

Proposal 2: To approve, on a    13,970,068     2,861,604      1,174,856          0
non-binding, advisory basis,
the compensation that will
or may become payable by
Sierra Oncology to its named
executive officers in
connection with the Merger.

Proposal 2 received the
necessary votes to be
approved.

In light of the approval of Proposal 1, Proposal 3 described in Sierra Oncology's definitive proxy statement (relating to the adjournment of the Special Meeting) was rendered moot and was not presented at the Special Meeting.

--------------------------------------------------------------------------------

Item 8.01 Other Events.

As previously disclosed, under the terms of the Merger Agreement, the consummation of the Merger will take place no later than the second business day after the satisfaction of the closing conditions under the Merger Agreement unless another date is agreed in writing by Sierra Oncology and GSK. As a result of the adoption by Sierra Oncology's stockholders of the Merger Agreement, the Merger is expected to be consummated on July 1, 2022 before market open, subject to the satisfaction of the remaining customary closing conditions.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses